About 5-hydroxytryptamine receptor 1E
5-hydroxytryptamine receptor 1E (HTR1E) is a protein
from Homo sapiens identified by UniProt accession
P28566, 365 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 1E |
| UniProt accession | P28566 |
| Gene | HTR1E |
| Organism | Homo sapiens |
| Length | 365 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (50)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.59
- schizoaffective disorder · score 0.50
- post operative nausea and vomiting · score 0.47
- depressive disorder · score 0.43
- obesity · score 0.37
- movement disorder · score 0.37
- psychosis · score 0.37
- unipolar depression · score 0.37
- mental or behavioural disorder · score 0.37
- Nausea and vomiting · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28566-F1 | alphafold | PREDICTED | 78.46 | — |
Amino-acid sequence (365 residues)
MNITNCTTEA SMAIRPKTIT EKMLICMTLV VITTLTTLLN LAVIMAIGTT KKLHQPANYL ICSLAVTDLL VAVLVMPLSI IYIVMDRWKL GYFLCEVWLS VDMTCCTCSI LHLCVIALDR YWAITNAIEY ARKRTAKRAA LMILTVWTIS IFISMPPLFW RSHRRLSPPP SQCTIQHDHV IYTIYSTLGA FYIPLTLILI LYYRIYHAAK SLYQKRGSSR HLSNRSTDSQ NSFASCKLTQ TFCVSDFSTS DPTTEFEKFH ASIRIPPFDN DLDHPGERQQ ISSTRERKAA RILGLILGAF ILSWLPFFIK ELIVGLSIYT VSSEVADFLT WLGYVNSLIN PLLYTSFNED FKLAFKKLIR CREHT
Explore 5-hydroxytryptamine receptor 1E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets